Ainos

Predictability is low. H1 2026 revenue was $313 with a net loss of $7.05 million, and the company continues to highlight future revenue opportunities in 2H 2026 rather than consistent organic growth. The industrial pipeline is promising but customer conversions, deployment pacing, and retention are unclear.

The therapeutics arm introduces regulatory, clinical, and timing risks despite Orphan Drug Designation for VELDONA in HIV-related oral warts. Geographic exposure is primarily Taiwan and Asia for semiconductor deployments, adding FX and geopolitical variables. We do not see a tollbooth-like revenue model in the data yet.